CN107641651B - Application of brain glioma temozolomide drug resistance detection marker molecule SCD1 - Google Patents

Abstract

The invention provides application of a brain glioma temozolomide drug resistance detection marker molecule SCD 1. In particular to a reagent for detecting the expression quantity of SCD1 in brain glioma cells, which is used for preparing a preparation for predicting the drug resistance of brain glioma to temozolomide, and an application of an inhibitor of SCD1 in preparing a preparation for promoting the drug resistance sensitivity of brain glioma to temozolomide. The invention discovers that the expression quantity of SCD1 in the brain glioma cells is related to the drug resistance of the brain glioma to the temozolomide for the first time, and discovers that the inhibitor of SCD1 can promote the drug resistance sensitivity of the brain glioma to the temozolomide. Has important significance for the research of the treatment of the brain glioma.

Description

Application of the marker molecule SCD1 in the detection of temozolomide resistance in gliomas

technical field

The invention belongs to the technical field of biomedicine, and relates to the application of a marker molecule SCD1 for detecting the drug resistance of temozolomide in brain glioma. Specifically, it relates to a reagent for detecting the expression of SCD1 in glioma cells for the preparation of preparations for predicting the resistance of gliomas to temozolomide, and the use of SCD1 inhibitors in the preparation of preparations for promoting the sensitivity of gliomas to temozolomide resistance application on.

Background technique

Gliomas are malignant progressive astrocytomas and one of the leading causes of cancer-related deaths in adults and young children worldwide. After initial diagnosis, the median survival time for glioma patients is approximately 12-15 months. At present, the traditional treatment methods for glioma patients mainly include surgical resection, radiotherapy and chemotherapy. Although these treatment methods can prolong the median survival time of patients to 14.6 months, the treatment effect is not ideal, and the patients are easy to suffer after treatment. recurrence, resulting in a poor prognosis. Since 2005, temozolomide (TMZ) has been used as a first-line drug for patients with glioma. However, temozolomide resistance during treatment is the main cause of chemotherapy failure. Therefore, overcoming temozolomide resistance is important for improving brain The curative effect of glioma treatment is very important.

Stearoyl-coenzyme A desaturase 1 (SCD1) is a key rate-limiting enzyme in the synthesis of intracellular monounsaturated fatty acids, and participates in tumor cell proliferation, differentiation, and apoptosis by regulating intracellular lipid metabolism pathways. biological behavior such as death. The present invention finds for the first time that the expression of SCD1 in glioma cells is related to the resistance of glioma to temozolomide, and it is found that the inhibitor of SCD1 can promote the sensitivity of glioma to temozolomide resistance. It is of great significance for the study of glioma treatment.

SUMMARY OF THE INVENTION

The purpose of the present invention is to provide an application of the marker molecule SCD1 for the detection of temozolomide resistance in glioma. Specifically, it relates to a reagent for detecting the expression of SCD1 in glioma cells for the preparation of preparations for predicting the resistance of gliomas to temozolomide, and the use of SCD1 inhibitors in the preparation of preparations for promoting the sensitivity of gliomas to temozolomide resistance application on.

The application of the marker molecule SCD1 for the detection of temozolomide resistance in glioma, and the reagent for detecting the expression of SCD1 in glioma cells is used to prepare a preparation for predicting the resistance of glioma to temozolomide.

qPCR or western blot detection reagent for detecting the expression of SCD1 in glioma cells.

The primer sequences in the qPCR reagent to detect the expression of SCD1 are: upstream primer 5'-TCTAGCTCCTATACCACCACCA-3'; downstream primer 5'-TCGTCTCCAACTTATCTCCTCC-3'.

The application of SCD1 inhibitor in the preparation of preparations that promote the resistance and sensitivity of glioma to temozolomide.

The method for obtaining a glioma drug-resistant cell line in the present invention is as follows: taking human glioma cell lines U87 and T98G as induction objects, setting up different low-concentration temozolomide treatment groups to find the best initial concentration, and then following the steps of the first 10 times. The dosage of temozolomide was gradually increased at a concentration of 1 μM/L each time and 5 μM/L each time after the 11th time, until the stimulation with a high concentration of 100 μM/L temozolomide, and finally the human glioma temozolomide-resistant cell lines U87-R and T98G were obtained. -R. The constructed drug-resistant cell lines U87-R and T98G-R were used to evaluate SCD1 as a new marker molecule for temozolomide resistance.

The specific method for establishing a glioma temozolomide-resistant cell line of the present invention and the detection of temozolomide-related molecules are as follows:

(1) Take two human glioma cell lines U87 and T98G, and after resuscitation, use DMEM medium containing fetal bovine serum, and culture them in a carbon dioxide incubator at 37°C;

(2) Take the logarithmic growth phase cell lines U87 and T98G in good condition and inoculate them in 6-well plates respectively;

(3) The glioma cell lines U87 and T98G were treated with different lower concentrations of temozolomide (0, 0.01, 0.05, 0.1, 0.5, 1 μM/L), and passaged or changed the medium in time, so that the cells grew normally after the first addition of temozolomide The maximum concentration is the initial concentration (0.5 μM/L), and in the subsequent temozolomide treatment, the dosage of temozolomide is gradually increased according to the concentration of 1 μM/L each time for the first 10 times and 5 μM/L each time from the 11th time, until 100 μM After treatment with high concentration of temozolomide/L, the cells were screened for more than 2 months, and the cells that could still grow normally were defined as glioma temozolomide-resistant cell lines;

(4) Using the constructed glioma temozolomide-resistant cell lines U87-R and T98G-R to evaluate SCD1 as a new marker molecule for temozolomide resistance.

The maximum tolerated drug dose of the temozolomide-resistant cell line obtained by the present invention is 100 μM/L.

The temozolomide-resistant cell lines obtained by the present invention are named as U87-R and T98G-R.

The invention firstly evaluates the biological characteristics of glioma temozolomide-resistant cell lines U87-R and T98G-R through cell growth curve and IC50 value, and successfully constructs two U87-R and T98G-R cell lines.

In conclusion, the present invention discovers for the first time SCD1, a new marker molecule of temozolomide resistance in gliomas; it is found that the expression of SCD1 in glioma cells is related to the resistance of gliomas to temozolomide, and it is found that SCD1 inhibitors can promote the Glioma susceptibility to temozolomide resistance. It is of great significance for the study of glioma treatment.

The invention is beneficial to study the molecular mechanism of tumor resistance to temozolomide, the method for reversing tumor resistance, and to evaluate new antitumor drugs, etc., and has high scientific research and production application value.

Description of drawings

Figure 1A-B is the growth curve and IC50 value of glioma temozolomide-resistant cell lines treated with different concentrations of temozolomide; C-D is the glioma temozolomide-resistant cell lines treated with 100 μM/L temozolomide for different time Growth curve.

Figure 2 shows the temozolomide resistance-related marker molecule SCD1 in glioma temozolomide-resistant cell lines

detection.

Figure 3 shows the growth curves of SCD1-overexpressing glioma cell lines U87 and T98G after treatment with different high concentrations of temozolomide.

Figure 4 shows the growth curves of the temozolomide-resistant glioma cell lines U87-R and T98G-R targeting SCD1 knockout after treatment with different high concentrations of temozolomide.

Figure 5 shows that the SCD1 small molecule inhibitor A939572, an oral SCD1 inhibitor, significantly enhanced the inhibitory effect of temozolomide on glioma temozolomide-resistant cell lines.

Detailed ways

The glioma cell lines U87 and T98G used in the present invention are collected by Xiangya Hospital of Central South University, and the temozolomide-resistant cell lines U87-R and T98G-R are constructed by the present invention.

Example 1 The IC50 of glioma temozolomide-resistant cell line is significantly increased

IC50 (half maximal inhibitory concentration) refers to the concentration at which the measured drug induces 50% tumor cell death. The IC50 value can be used to measure the ability of the drug to induce apoptosis, that is, the stronger the pro-apoptotic ability, the lower the value, indicating that the drug The better the sensitivity, of course, it can also indicate the degree of resistance of a certain cell to the drug. The parental cell line and glioma temozolomide-resistant cell line were treated with different concentrations of temozolomide, and the IC50 value of temozolomide was calculated from the cell growth curve to confirm the successful construction of temozolomide-resistant glioma temozolomide cell line. time to further validate the construction of glioma temozolomide-resistant cell lines.

The experimental method is as follows: Brain glioma cells are cultured in a 96-well plate, and when 70-80% confluent, the cells are treated with temozolomide at a concentration of 0.2, 2, 20, 200, 2000 μM/L for 0, 24, 48, 72 h, or The cells were treated with 100 μM/L temozolomide for different time periods of 0, 1, 2, 3, 4, and 5 days, then 20 μL of MTS reagent was added, and incubated for 4 h. The absorbance was measured at a wavelength of 490 nm, the cell growth curve was drawn, and temozolomide was calculated. IC50 value.

The results showed that compared with the parental cell lines U87 and T98G, the inhibitory efficiency of temozolomide on the glioma temozolomide-resistant cell lines U87-R and T98G-R was lower, and the IC50 showed that the T98G was 464.4±13.73, and the T98G-R was 1716.0± 13.97, U87 was 433.7±15.16, and U87-R was 1431.0±24.54, indicating that the IC50 values of temozolomide-resistant cell lines U87-R and T98G-R were significantly higher than those of parental cell lines U87 and T98G, suggesting that drug-resistant cells Lines U87-R and T98G-R were successfully established. The results are shown in Figure 1.

Example 2 High expression of SCD1 in temozolomide-resistant cell lines

Studies have shown that SCD1 is involved in the occurrence and development of tumors by regulating fatty acid metabolism. The expression levels of SCD1 in glioma temozolomide-resistant cell lines were evaluated by qPCR and western blot, respectively.

The experimental method is as follows:

2.1 Find the full-length mRNA sequence of SCD1 gene

SCD1 was searched in the PUBMED Nucleotide database, and the full-length SCD1 mRNA of human (Homo sapiens) was selected.

2.2 Design SCD1 primers

In PrimerBank database, select NCBI Gene Symbol, species select human source (Homo sapiens), For text input SCD1; or select GenBank Accession, species select human source (Homo sapiens), For text input NM_005063. Both design methods obtained the following primer sequences for SCD1:

2.3 Extract the total RNA and total protein of the glioma temozolomide-resistant cell lines and parental cell lines, and use qPCR and western blot techniques to detect the expression level of SCD1.

The results showed that the transcription level and protein translation level of SCD1 were significantly increased in the glioma temozolomide-resistant cell line compared with the parental cell line. The results are shown in Figure 2.

Example 3 SCD1 overexpression can block the inhibitory effect of temozolomide on parental cell lines

In order to determine whether overexpression of SCD1 affects the responsiveness of parental cell lines to temozolomide, the antitumor effect of temozolomide after overexpression of SCD1 in parental cell lines was detected by drawing a survival curve, and the effect of overexpression of SCD1 in parental cell lines on the efficacy of temozolomide was evaluated. .

The experimental method is as follows: the parental cell line of glioma in good condition and in the logarithmic growth phase is taken, overexpressing SCD1, and then cultured in a 96-well plate. When it reaches 70-80% confluence, different high concentrations of temozolomide are used to treat it. The cell line was then added with 20 μL of MTS reagent, incubated for 4 h, the absorbance value was measured at a wavelength of 490 nm, the cell growth curve was drawn, and the IC50 value of temozolomide was calculated.

The results showed that compared with the transfection blank plasmid pcDNA3.1, the two parental cell lines overexpressing SCD1 were resistant to temozolomide to a certain extent. The IC50 showed that T98G/pcDNA3.1 was 649.8±8.40, SCD1 was 1070.0±6.75, U87/pcDNA3.1 was 553.2±14.91, and U87/pcDNA-SCD1 was 1325±14.85, suggesting that SCD1 overexpression can block the sensitivity of parental cell lines to temozolomide. The results are shown in Figure 3.

Example 4 Targeted knockout of SCD1 can significantly reverse temozolomide resistance

In order to determine whether targeted knockout of SCD1 affects the responsiveness of glioma temozolomide-resistant cell lines to temozolomide, the anti-tumor effect of temozolomide after targeted knockout of SCD1 in temozolomide-resistant cells was detected and evaluated by drawing a survival curve. Effects of targeted knockdown of SCD1 on the efficacy of temozolomide.

The experimental method is as follows: take a glioma temozolomide-resistant cell line in good condition and in the logarithmic growth phase, use siRNA to target and knock out SCD1, and then culture it in a 96-well plate. When it reaches 70-80% confluence, use Cell lines were treated with different high concentrations of temozolomide, then 20 μL of MTS reagent was added, incubated for 4 h, the absorbance was measured at a wavelength of 490 nm, the cell growth curve was drawn, and the IC50 value of temozolomide was calculated.

The results showed that compared with the si-Ctrl control group (that is, the ineffective siRNA group), different concentrations of temozolomide could significantly inhibit the proliferation of two temozolomide-resistant cell lines using siRNA to target and knock down SCD1. The IC50 showed that T98G-R/ si-Ctrl was 1829.0±19.33, T98G-R/si-SCD1 was 409.8±6.36, U87-R/si-Ctrl was 1642.0±12.28, U87-R/si-SCD1 was 726.3±13.09, suggesting targeted knockout of SCD1 Can promote the sensitivity of temozolomide-resistant cell lines to temozolomide. The results are shown in Figure 4.

Example 5 SCD1 small molecule inhibitor A939572 can significantly reverse the resistance of temozolomide

In order to further clarify the role of SCD1 in temozolomide resistance in brain gliomas and develop effective small molecule inhibitors, the effect of SCD1 small molecule inhibitor A939572 on the antitumor effect of temozolomide was detected by cell viability assay, and the SCD1 small molecule was evaluated. Potential of inhibitors as sensitizers for temozolomide resistance.

The experimental method is as follows: take the glioma temozolomide-resistant cell line in good condition and in the logarithmic growth phase, then culture it in a 96-well plate, and treat the cells with different concentrations of temozolomide and A939572 when the confluence reaches 70-80%. 20 μL of MTS reagent was added respectively, incubated for 4 h, the absorbance value was measured at the wavelength of 490 nm, and the cell growth curve was drawn.

The results showed that compared with the DMSO control group (ie, the solvent group without A939572), A939572 at different concentrations could significantly inhibit the proliferation of two temozolomide-resistant cell lines, and when used in combination with temozolomide, A939572 could significantly enhance temozolomide The inhibitory effect on glioma temozolomide-resistant cells suggested that A939572, a small molecule inhibitor of SCD1, could promote the sensitivity of temozolomide-resistant cell lines to temozolomide. The results are shown in Figure 5.

SEQUENCE LISTING

<110> Central South University Xiangya Hospital

<120> Application of marker molecule SCD1 for detection of temozolomide resistance in glioma

<130> None

<160> 3

<170> PatentIn version 3.3

<210> 1

<211> 5473

<212> DNA

<213> Gene mRNA full-length sequence of SCD1

<400> 1

ggcaggacga ggtggcacca aattcccttc ggccaatgac gagccggagt ttacagaagc 60

ctcattagca tttccccaga ggcaggggca ggggcagagg ccgggtggtg tggtgtcggt 120

gtcggcagca tccccggcgc cctgctgcgg tcgccgcgag cctcggcctc tgtctcctcc 180

ccctcccgcc cttacctcca cgcgggaccg cccgcgccag tcaactcctc gcactttgcc 240

cctgcttggc agcggataaa agggggctga ggaaataccg gacacggtca ccgttgcca 300

gctctagcct ttaaattccc ggctcgggga cctccacgca ccgcggctag cgccgacaac 360

cagctagcgt gcaaggcgcc gcggctcagc gcgtaccggc gggcttcgaa accgcagtcc 420

tccggcgacc ccgaactccg ctccggagcc tcagccccct ggaaagtgat cccggcatcc 480

gagagccaag atgccggccc acttgctgca ggacgatatc tctagctcct ataccaccac 540

caccaccatt acagcgcctc cctccagggt cctgcagaat ggaggagata agttggagac 600

gatgcccctc tacttggaag acgacattcg ccctgatata aaagatgata tatatgaccc 660

cacctacaag gataaggaag gcccaagccc caaggttgaa tatgtctgga gaaacatcat 720

ccttatgtct ctgctacact tgggagccct gtatgggatc actttgattc ctacctgcaa 780

gttctacacc tggctttggg gggtattcta ctattttgtc agtgccctgg gcataacagc 840

aggagctcat cgtctgtgga gccaccgctc ttacaaagct cggctgcccc tacggctctt 900

tctgatcatt gccaacacaa tggcattcca gaatgatgtc tatgaatggg ctcgtgacca 960

ccgtgcccac cacaagtttt cagaaacaca tgctgatcct cataattccc gacgtggctt 1020

tttcttctct cacgtgggtt ggctgcttgt gcgcaaacac ccagctgtca aagagaaggg 1080

gagtacgcta gacttgtctg acctagaagc tgagaaactg gtgatgttcc agaggaggta 1140

ctacaaacct ggcttgctga tgatgtgctt catcctgccc acgcttgtgc cctggtattt 1200

ctggggtgaa acttttcaaa acagtgtgtt cgttgccact ttcttgcgat atgctgtggt 1260

gcttaatgcc acctggctgg tgaacagtgc tgcccacctc ttcggatatc gtccttatga 1320

caagaacatt agcccccggg agaatatcct ggtttcactt ggagctgtgg gtgagggctt 1380

ccacaactac caccactcct ttccctatga ctactctgcc agtgagtacc gctggcacat 1440

caacttcacc acattcttca ttgattgcat ggccgccctc ggtctggcct atgaccggaa 1500

gaaagtctcc aaggccgcca tcttggccag gattaaaaga accggagatg gaaactacaa 1560

gagtggctga gtttggggtc cctcaggttc ctttttcaaa aaccagccag gcagaggttt 1620

taatgtctgt ttattaacta ctgaataatg ctaccaggat gctaaagatg atgatgttaa 1680

cccattccag tacagtattc ttttaaaatt caaaagtatt gaaagccaac aactctgcct 1740

ttatgatgct aagctgatat tatttcttct cttatcctct ctctcttcta ggcccattgt 1800

cctccttttc actttattgc tatcgccctc ctttccctta ttgcctccca ggcaagcagc 1860

tggtcagtct ttgctcagtg tccagcttcc aaagcctaga caacctttct gtagcctaaa 1920

acgaatggtc tttgctccag ataactctct ttccttgagc tgttgtgagc tttgaagtag 1980

gtggcttgag ctagagataa aacagaatct tctgggtagt cccctgttga ttatcttcag 2040

cccaggcttt tgctagatgg aatggaaaag caacttcatt tgacacaaag cttctaaagc 2100

aggtaaattg tcgggggaga gagttagcat gtatgaatgt aaggatgagg gaagcgaagc 2160

aagaggaacc tctcgccatg atcagacata cagctgccta cctaatgagg acttcaagcc 2220

ccaccacata gcatgcttcc tttctctcct ggctcggggt aaaaagtggc tgcggtgttt 2280

ggcaatgcta attcaatgcc gcaacatata gttgaggccg aggataaaga aaagacattt 2340

taagtttgta gtaaaagtgg tctctgctgg ggaagggttt tcttttcttt ttttctttaa 2400

taacaaggag atttcttagt tcatatatca agaagtcttg aagttgggtg tttccagaat 2460

tggtaaaaac agcagctcat agaattttga gtattccatg agctgctcat tacagttctt 2520

tcctctttct gctctgccat cttcaggata ttggttcttc ccctcatagt aataagatgg 2580

ctgtggcatt tccaaacatc caaaaaaagg gaaggattta aggaggtgaa gtcgggtcaa 2640

aaataaaata tatatacata tatacattgc ttagaacgtt aaactattag agtatttccc 2700

ttccaaagag ggatgtttgg aaaaaactct gaaggagagg aggaattagt tgggatgcca 2760

atttcctctc cactgctgga catgagatgg agaggctgag ggacaggatc tataggcagc 2820

ttctaagagc gaacttcaca taggaaggga tctgagaaca cgttgccagg ggcttgagaa 2880

ggttactgag tgagttattg ggagtcttaa taaaataaac tagatattag gtccattcat 2940

taattagttc cagtttctcc ttgaaatgag taaaaactag aaggcttctc tccacagtgt 3000

tgtgcccctt cactcatttt tttttgagga gaagggggtc tctgttaaca tctagcctaa 3060

agtatacaac tgcctggggg gcagggttag gaatctcttc actaccctga ttcttgattc 3120

ctggctctac cctgtctgtc ccttttcttt gaccagatct ttctcttccc tgaacgtttt 3180

cttctttccc tggacaggca gcctcctttg tgtgtattca gaggcagtga tgacttgctg 3240

tccaggcagc tccctcctgc acacagaatg ctcagggtca ctgaaccact gcttctcttt 3300

tgaaagtaga gctagctgcc actttcacgt ggcctccgca gtgtctccac ctacacccct 3360

gtgctcccct gccacactga tggctcaaga caaggctggc aaaccctccc agaaacatct 3420

ctggcccaga aagcctctct ctccctccct ctctcatgag gcacagccaa gccaagcgct 3480

catgttgagc cagtgggcca gccacagagc aaaagagggt ttattttcag tcccctctct 3540

ctgggtcaga accagagggc atgctgaatg ccccctgctt acttggtgag ggtgccccgc 3600

ctgagtcagt gctctcagct ggcagtgcaa tgcttgtaga agtaggagga aacagttctc 3660

actgggaaga agcaagggca agaacccaag tgcctcacct cgaaaggagg ccctgttccc 3720

tggagtcagg gtgaactgca aagctttggc tgagacctgg gatttgagat accacaaacc 3780

ctgctgaaca cagtgtctgt tcagcaaact aaccagcatt ccctacagcc tagggcagac 3840

aatagtatag aagtctggaa aaaaacaaaa acagaatttg agaaccttgg accactcctg 3900

tccctgtagc tcagtcatca aagcagaagt ctggctttgc tctattaaga ttggaaatgt 3960

acactaccaa acactcagtc cactgttgag ccccagtgct ggaagggagg aaggcctttc 4020

ttctgtgtta attgcgtaga ggctacaggg gttagcctgg actaaaggca tccttgtctt 4080

ttgagctatt cacctcagta gaaaaggatc taagggaaga tcactgtagt ttagttctgt 4140

tgacctgtgc acctacccct tggaaatgtc tgctggtatt tctaattcca caggtcatca 4200

gatgcctgct tgataatata taaacaataa aaacaacttt cacttcttcc tattgtaatc 4260

gtgtgccatg gatctgatct gtaccatgac cctacataag gctggatggc acctcaggct 4320

gagggcccca atgtatgtgt ggctgtgggt gtgggtggga gtgtgtctgc tgagtaagga 4380

acacgatttt caagattcta aagctcaatt caagtgacac attaatgata aactcagatc 4440

tgatcaagag tccggatttc taacagtcct tgctttgggg ggtgtgctga caacttagct 4500

caggtgcctt acatcttttc taatcacagt gttgcatatg agcctgccct cactccctct 4560

gcagaatccc tttgcacctg agaccctact gaagtggctg gtagaaaaag gggcctgagt 4620

ggaggattat cagtatcacg atttgcagga ttcccttctg ggcttcattc tggaaacttt 4680

tgttagggct gcttttctta agtgcccaca tttgatggag ggtggaaata atttgaatgt 4740

atttgattta taagtttttt tttttttttt gggttaaaag atggttgtag catttaaaat 4800

ggaaaatttt ctccttggtt tgctagtatc ttgggtgtat tctctgtaag tgtagctcaa 4860

ataggtcatc atgaaaggtt aaaaaagcga ggtggccatg ttatgctggt ggttaaggcc 4920

agggcctctc caaccactgt gccactgact tgctgtgtga ccctgggcaa gtcacttaac 4980

tataaggtgc ctcagttttc cttctgttaa aatggggata ataatactga cctacctcaa 5040

agggcagttt tgaggcatga ctaatgcttt ttagaaagca ttttgggatc cttcagcaca 5100

ggaattctca agacctgagt atttttttata ataggaatgt ccaccatgaa cttgatacgt 5160

ccgtgtgtcc cagatgctgt cattagtcta tatggttctc caagaaactg aatgaatcca 5220

ttggagaagc ggtggataac tagccagaca aaatttgaga atacataaac aacgcattgc 5280

cacggaaaca tacagaggat gccttttctg tgattgggtg ggattttttc ccttttttatg 5340

tgggatatag tagttacttg tgacaagaat aattttggaa taatttctat taatatcaac 5400

tctgaagcta attgtactaa tctgagattg tgtttgttca taataaaagt gaagtgaatc 5460

tgattgcaaa aaa 5473

<210> 2

<211> 22

<212> DNA

<213> Upstream primers in qPCR reagents for detecting SCD1 expression

<400> 2

tctagctcct ataccaccac ca 22

<210> 3

<211> 22

<212> DNA

<213> Downstream primers in qPCR reagents for detecting SCD1 expression

<400> 3

tcgtctccaa cttatctcct cc 22

Claims (4)

1. The application of a brain glioma temozolomide drug resistance detection marker molecule SCD1 is characterized in that the application is that a reagent for detecting the expression quantity of SCD1 in brain glioma cells is used for preparing a preparation for predicting the drug resistance of brain glioma to temozolomide.

2. The use according to claim 1, wherein the reagent for detecting the expression level of SCD1 in brain glioma cells is a qPCR or western blot detection reagent.

3. The use according to claim 2, wherein the primer sequence of the qPCR reagent for detecting the expression level of SCD1 is: an upstream primer 5'-TCTAGCTCCTATACCACCACCA-3'; the downstream primer 5'-TCGTCTCCAACTTATCTCCTCC-3'.

Use of an inhibitor of SCD1 in the preparation of a formulation for promoting brain glioma sensitivity to temozolomide.

Images